809 Results
FDA opens a public docket on drug repurposing, targeting labeling updates for approved medicines across metabolic, rare, and neurodegenerative disease areas.
Vaibhavi M. | May 11, 2026
Reunion Neuroscience targets 2026 Phase 3 initiation for luvesilocin in PPD after FDA Breakthrough Designation and single-trial registrational agreement.
Vaibhavi M. | May 11, 2026
FibroBiologics expands its fibroblast platform into Hantavirus pulmonary syndrome, leveraging ARDS preclinical data where no approved treatments exist.
Vaibhavi M. | May 11, 2026
Abeona Therapeutics adds CHOP as its sixth ZEVASKYN Qualified Treatment Center, expanding autologous gene therapy access on the US east coast.
Vaibhavi M. | May 11, 2026
Miror Therapeutics partners with BESCOM and Soham Foundation to deliver menopause and HRT awareness at BESCOM's Bengaluru headquarters.
Vaibhavi M. | May 11, 2026
Abbott brings catheter-based tricuspid valve repair to India, creating new device governance and procurement obligations for cardiac programs.
Vaibhavi M. | May 11, 2026
Robocath closes first-in-human enrollment for its robotic PCI platform in France, advancing toward regulatory submission.
Vaibhavi M. | May 11, 2026